Aaron M. Gruber

Notable transactions include representing:

• Future Standard in its acquisition of the Digital Infrastructure platform of Post Road Group; its combination with Portfolio Advisors, creating a $75 billion alternative investment firm; and in the transition of the management of its business development company (BDC) platform to investment advisory partnerships with EIG Global Energy Partners and KKR;
  
  
• Viatris in its divestitures totaling $6.94 billion in value, including the $3.335 billion combination of its biosimilars portfolio with Biocon Biologics and the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;
  
  
• Mylan in its $50 billion combination with Upjohn, a division of Pfizer, to form Viatris, its acquisition of global marketing rights to GA Depot through an investment in and partnership with Mapi Pharma, its $9.9 billion acquisition of Meda, its acquisition of the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings for $950 million in cash at closing plus additional contingent payments of up to $50 million, its successful takeover defense against Teva’s $40 billion hostile bid, its proposal to acquire Perrigo in a transaction valued at approximately $35 billion, its $5.6 billion inversion acquisition of Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business and its $550 million acquisition of Bioniche Pharma;

• Unilever in its acquisition of a majority stake in Nutrafol, its acquisition of OLLY Nutrition, its acquisition of Sundial Brands, its $384 million acquisition of the TAZO brand from Starbucks, its acquisition of Seventh Generation, its acquisition of Murad, its acquisition of Dermalogica, its acquisition of Talenti Gelato & Sorbetto, the $2.15 billion sale of its North America pasta sauces business under the Ragú and Bertolli brands to Mizkan Group and its $3.7 billion acquisition of Alberto‑Culver;
  
  
• Axalta in its pending $25 billion merger of equals with AkzoNobel;
  
  
• Fitch Learning, a subsidiary of Hearst, in its pending acquisition of Moody’s Analytics Learning Solutions and the Canadian Securities Institute;
  
  
• Vista Outdoor in the $2.225 billion sale of The Kinetic Group to Czechoslovak Group and the $1.125 billion sale of Revelyst to SVP;
  
  
• HCSC in its $3.3 billion acquisition of Cigna’s Medicare businesses and CareAllies;
  
  
• Biogen in its $7.3 billion acquisition of Reata Pharmaceuticals;
  
  
• The Snyder family in the $6.05 billion sale of the NFL’s Washington Commanders to a partnership led by Josh Harris;
  
  
• RWE in its $6.8 billion acquisition of the Con Edison Clean Energy Businesses; 
   
• Evolent Health in its cooperation agreement with Engaged Capital;
  
  
• The Aquarion Water Authority in its pending $2.4 billion acquisition of Aquarion Water Company from Eversource Energy;
  
  
• The special committee of the board of directors of EchoStar in the $26 billion combination with DISH Network;
  
  
• BDT and its affiliates in the take-private acquisition of Weber, valuing Weber at $3.7 billion;
  
  
• Atalaya Capital Management in its $800 million sale to Blue Owl Capital;
  
  
• Thrivent in its acquisition of a majority stake in College Avenue;
  
  
• Cowen in its $1.9 billion acquisition by TD;
  
  
• Convey Health Solutions in its $1.1 billion take‑private acquisition by TPG Capital;
  
  
• Schneider Electric in its acquisition of AutoGrid;
• RELX Group in its acquisition of Human API, its acquisition of Interfolio, its acquisition of BehavioSec, its acquisition of Osmosis, its acquisition of Shadow Health, its acquisition of Emailage, its $375 million acquisition of ID Analytics, its acquisition of Aries Systems, its acquisition of Safe Banking Systems, its £580 million acquisition of ThreatMetrix, its acquisition of bepress and LexisNexis Legal & Professional’s joint ventures with Knowable and LEAP Legal Software;
  
  
• The independent members of the Neenah board of directors in the $3 billion combination with SWM;
  
  
• NRG Energy in its cooperation agreement with Elliott Management;
  
  
• Corteva in its agreement with Starboard;
  
  
• Eurazeo in its acquisition of Scaled Agile and its acquisition of WorldStrides;
  
  
• Ulta Beauty in its strategic partnership with Target;
• The special committee of the board of Eidos Therapeutics in the $2.83 billion merger with BridgeBio Pharma;

• Barrick Gold in its proposed $42 billion merger and subsequent joint venture with Newmont Mining;

• Deutsche Börse in its €3.9 billion acquisition of SimCorp, the combination of ISS and Qontigo’s index business as ISS STOXX, its previous $2.275 billion acquisition of ISS and its $850 million acquisition of Axioma;

• Linde in its $70 billion merger of equals with Praxair, its acquisition of American HomePatient and its $4.6 billion acquisition of Lincare Holdings;
  
  
• Knorr-Bremse in its $149.5 million acquisition of R.H. Sheppard and the sale of R.H. Sheppard to Balmoral Funds;

• KION Group in its $2.1 billion acquisition of Dematic from funds managed by AEA Investors and Ontario Teachers’ Pension Plan;

• Cigna in its proposed $54.2 billion merger with Anthem;

• Element Financial in its acquisition of PHH Arval, PHH Corporation’s North American fleet management services business, for $1.4 billion in cash and the assumption of $3.5 billion of PHH Arval debt;

• The special committee of the board of directors of Assisted Living Concepts in the $485 million sale to TPG Capital;

• Gerber Scientific in its $283 million sale to Vector Capital;

• Novartis in its $470 million acquisition of Genoptix;

• Biovail Pharmaceuticals in its $6.5 billion merger of equals with Valeant Pharmaceuticals;

• EMBARQ in its $11.6 billion merger with CenturyTel;

• Alpharma in the $395 million sale of its active pharmaceutical ingredients business to 3i; and

• Alcoa in the $2.7 billion sale of its packaging and consumer business to Rank Group.